Advances in pancreatic cancer biomarkers
Oncology Reviews · 01.02.2019 · 13 (1)
DOI: 10.4081/oncol.2019.410 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Reviews, online erschienen am 01.02.2019. Verfasst von Syed Hasan und 3 weiteren Autor:innen. Beteiligte Einrichtung: University of Alabama at Birmingham, USA. Die Arbeit wurde bisher 108-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Biomarkers play an essential role in the management of patients with invasive cancers. Pancreatic ductal adenocarcinoma (PDC) associated with poor prognosis due to advanced presentation and limited therapeutic options. This is further complicated by absence of validated screening and predictive biomarkers for early diagnosis and precision treatments respectively. There is emerging data on biomarkers in pancreatic cancer in past two decades. So far, the CA 19-9 remains the only approved biomarker for diagnosis and response assessment but limited by low sensitivity and specificity. In this article, we aim to review current and future biomarkers that has potential serve as critical tools for early diagnostic, predictive and prognostic indications in pancreatic cancer.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of Alabama at Birmingham, USA.
Zitieren
APA
Hasan, S., Jacob, R., Manne, U., & Paluri, R. (2019). Advances in pancreatic cancer biomarkers. Oncology Reviews, 13(1). https://doi.org/10.4081/oncol.2019.410
Vancouver
Hasan S, Jacob R, Manne U, Paluri R. Advances in pancreatic cancer biomarkers. Oncology Reviews. 2019;13(1). doi:10.4081/oncol.2019.410
BibTeX
@article{Hasan2019,
author = {Hasan, Syed and Jacob, Rojymon and Manne, Upender and Paluri, Ravi},
title = {Advances in pancreatic cancer biomarkers},
journal = {Oncology Reviews},
year = {2019},
volume = {13},
number = {1},
doi = {10.4081/oncol.2019.410}
}
EUVIMED